Search Results

Multiply Labs and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced a non-exclusive partnership focused on automating and standardizing the use of cytokines in cell therapy manufacturing.

Akron Bio today announced the appointment of Christopher Murphy as Chief Executive Officer.

Akron Bio (“Akron”), a leading supplier of critical inputs for cell and gene therapies, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted Akron Eligibility Confirmation for its cGMP Virus Inactivated Human Fibronectin.

At Johns Hopkins University, the biomedical engineering program’s Design Team offering lets undergraduates dive deep into clinical projects that can help them land industry jobs, get provisional patents or even start companies.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Akron Children’s Hospital has been awarded a three-year $1.3 million grant from the National Institutes of Health /National Institute of Nursing Research to better define the practices of high-quality pediatric palliative care, particularly in seeking out the voices of the children, teens and young adults at the center of that care.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

Akron Bio, a leading developer and manufacturer of critical building blocks used by biopharma to produce advanced therapies for the prevention and treatment of cardiovascular diseases and cancers, launched a new, state-of-the-art cGMP plasmid DNA manufacturing facility in Sarasota, Florida.